PaxMedica Overview
Latest ROE for PaxMedica: 977.01% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow977.01%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
PaxMedica (PXMD) currently reports a ROE of 977.01%. That is above the sector sector average of -5.72%. Use the charts on this page to explore PaxMedica's ROE history and peer comparisons.
PaxMedica's ROE of 977.01% is higher than the its sector sector average of -5.72%. That is roughly 17173.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but PaxMedica's current 977.01% should be judged against industry norms (sector average: -5.72%) and against PXMD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 977.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.72%. From there, open related valuation or income-statement pages for PaxMedica, and consider following PXMD for alerts when major investors trade the stock.
